期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Cytochrome P450 2C19与氯吡格雷抵抗的研究

Research Developments in Cytochrome P450 2C19 and Clopidogrel Resistance
下载PDF
导出
摘要 氯吡格雷是一种新型噻吩吡啶类衍生物,可选择性不可逆地抑制二磷酸腺苷诱导的血小板聚集。Cytochrome P4502C19具有遗传多态性,Cytochrome P450 2C19*2等位基因变异所编码的功能缺陷性药物代谢酶与氯吡格雷抗血小板聚集的效果减弱有关。 Clopidogrel is a new orally administered thienopyridine derivative that selectively and irreversibly inhibits ADP-induced platelet aggregation.Cytochrome P450 2C19 is very polymorphic,and the cytochrome P450 2C19＊2 allelic variant encoding a deficient drug-metabolizing enzyme is associated with the impaired antiplatelet effect of clopidogrel.
作者 段兵 崔炜 都军
机构地区 河北医科大学第二医院心脑血管病研究所心内科
出处 《心血管病学进展》 CAS 2010年第3期472-475,共4页 Advances in Cardiovascular Diseases
关键词 细胞色素P450 2C19 氯吡格雷 基因多态性 血小板聚集抑制 cytochrome P450 2C19 clopidogrel polymorphsim inhibition of platelet aggregation
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献43

  • 1Wrighton SA,Stevens JC,Becker GW,et al.Isolation and characterization of human liver cytochrome P450 2C19:correlation between 2C19 and S-mephenytoin 4'-hydroxylation[J].Arch Biochem Biophys,1993,306(1):240-245.
  • 2Wilkinson GR,Guengerich FP,Branch RA.Genetic polymorphism of S-mephenytoin hydroxylation[J].Pharmacol Ther,1989,43(1):53-76.
  • 3Hulot JS,Bura A,Villard E,et al.Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects[J].Blood,2006,108(7):2244-2247.
  • 4Xiao ZS,Goldstein JA,Xie HG,et al.Differences in the incidence of theCYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Hanand Bai populations and identification of a new rare CYP2C19 mutant allele[J].J Pharmacol Exp Ther,1997,281(1):604-609.
  • 5de Morais SM,Wilkinson GR,Blaisdell J,et al.The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J].J Biol Chem,1994,269(22):15419-15422.
  • 6Chen ZM,Jiang LX,Chen YP,et al.Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction:randomised placebo-controlled trial[J].Lancet,2005,366(9497):1607-1621.
  • 7Sabatine MS,Cannon CP,Gibson CM,et al.Effect of clopidogrel pretreatmentbefore percutaneous coronary intervention in patients with ST-elevation myocar-dial infarction treated with fibrinolytics:the PCI-CLARITY study[J].JAMA,2005,294(10):1224-1232.
  • 8Frere C,Cuisset T,Morange PE,et al.Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome[J].Am J Cardiol,2008,101(8):1088-1093.
  • 9Harmsze A,van WJW,Bouman HJ,et al.Besides CYP2C19*2,the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation[J].Pharmacogenet Genomics,2010,20(1):18-25.
  • 10Giusti B,Gori AM,Marcucci R,et al.Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis[J].Am J Cardiol,2009,103(6):806-811.
心血管病学进展
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部